Drug Trial Radar · NCT01085812
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
734
Actual
Start
Mar 2010
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 12, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
Conditions
- Depression
- Major Depressive Disorder
Interventions
Levomilnacipran ERDrug
Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
PlaceboDrug
Matching placebo to be given orally, in capsule form, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Relapse (Days)Time frame: 24 Weeks
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
Forest Investigative Site #023
Beverly Hills, California
Forest Investigative Site #017
Encino, California
Forest Investigative Site #021
Garden Grove, California
Forest Investigative Site #025
Newport Beach, California
Forest Investigative Site #030
Orange, California
Forest Investigative Site #002
San Diego, California
Forest Investigative Site #003
Sherman Oaks, California
Forest Research Institute #001
Bonita Springs, Florida
Forest Investigative Site #015
Fort Myers, Florida
Forest Investigative Site #029
Maitland, Florida
Forest Investigative Site #005
North Miami, Florida
Forest Investigative Site #016
Orlando, Florida
Forest Investigative Site #004
South Miami, Florida
Forest Investigative Site #014
Atlanta, Georgia
Forest Investigative Site #022
Chicago, Illinois
Forest Investigative Site #006
Chicago, Illinois
Forest Investigative Site #009
Prairie Village, Kansas
Forest Investigative Site #013
Baltimore, Maryland
Forest Investigative Site #010
Boston, Massachusetts
Forest Investigative Site #012
St Louis, Missouri
Forest Investigative Site #011
Staten Island, New York
Forest Investigative Site #026
Portland, Oregon
Forest Investigative Site #008
Bridgeville, Pennsylvania
Forest Investigative Site #028
Norristown, Pennsylvania
Forest Investigative Site #020
Philadelphia, Pennsylvania
Forest Investigative Site #024
Memphis, Tennessee
Forest Investigative Site #007
Dallas, Texas
Forest Investigative Site #019
San Antonio, Texas
Forest Investigative Site #018
Bellevue, Washington
Forest Investigative Site #027
Seattle, Washington
Forest Investigative Site #050
Kelowna, British Columbia, Canada
Forest Investigative Site #051
Vancouver, British Columbia, Canada
Forest Investigative Site #052
Sydney, Nova Scotia, Canada
Forest Investigative Site #055
Chatham, Ontario, Canada
Forest Investigative Site #053
Ottawa, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.